Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization.
Chang Z, Guo X, Li X, Wang Y, Zang Z, Pei S, Lu W, Li Y, Huang JD, Xiao Y, Liu C.
Cell. 2025 Apr 3;188(7):1842-1857.e20. doi: 10.1016/j.cell.2025.02.002. Epub 2025 Mar 3.
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma.
Cai M, Wang Y, Ma H, Yang L, Xu Z.
Cancer Treat Rev. 2024 Dec;131:102840. doi: 10.1016/j.ctrv.2024.102840. Epub 2024 Oct 11.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML.
JAMA Oncol. 2023 Jan 1;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370.
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W.
Cancer Lett. 2021 Mar 1;500:1-10. doi: 10.1016/j.canlet.2020.12.024. Epub 2020 Dec 23.
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E, Zeppieri M, De Maria L, Tedeschi C, Fontanella MM, Panciani PP, Ius T.
Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037.
Colorectal cancer immunotherapy-Recent progress and future directions.
Zhao W, Jin L, Chen P, Li D, Gao W, Dong G.
Cancer Lett. 2022 Oct 1;545:215816. doi: 10.1016/j.canlet.2022.215816. Epub 2022 Jul 8.
Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
Liu Y, Zhou F, Ali H, Lathia JD, Chen P.
Cell Mol Immunol. 2024 Dec;21(12):1354-1375. doi: 10.1038/s41423-024-01226-x. Epub 2024 Oct 15.
Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies.
Seeneevassen L, Bessède E, Mégraud F, Lehours P, Dubus P, Varon C.
Int J Mol Sci. 2021 Mar 26;22(7):3418. doi: 10.3390/ijms22073418.
Glioblastoma at the crossroads: current understanding and future therapeutic horizons.
Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, Prasad S, Wang P, Singh A, Singh G.
Signal Transduct Target Ther. 2025 Jul 9;10(1):213. doi: 10.1038/s41392-025-02299-4.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS.
Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8.
